Table 2.

Prognostic significance of PD-L1 and p53 expression levels, along with clinical variables, in the radically resected pLELC cohort (n = 47)

Variables	n (%)	Median DFS/months	P
Age (mean ± SD, years)		54.4 ± 8.8
Age
<50 years	13 (27.6)	30.9 (15.6–46.2)	0.665
≥50 years	34 (72.4)	32.3 (24.2–40.4)
Gender
Female	29 (61.7)	32.3 (29.1–35.5)	0.666
Male	18 (38.3)	25.6 (11.9–39.3)
Smoking
Yes	12 (25.5)	25.6 (5.2–46.0)	0.466
No	35 (74.5)	30.9 (27.4–34.4)
Family history of cancer
Yes	6 (12.8)	45.7 (30.2–61.2)	0.242
No	41 (87.2)	29.8 (19.7–40.0)
Clinical stage
I	19 (40.4)	29.9 (11.4–48.3)	0.185
II		7 (14.9)	18.1 (1.0–35.5)
IIIA		21 (44.7)	35.4 (15.3–55.5)
PD-L1 in tumor cells
<1%	18 (38.3)	19.2 (16.4–22.0)	0.020*
1–49%		17 (36.2)	32.3 (19.6–45.0)
≥50%		12 (25.5)	57.6 (27.6–87.6)
p53
Wild type	21 (44.7)	45.1 (27.2–63.0)	0.033*
Mutation type		26 (55.3)	20.0 (3.2–36.7)

*P < 0.05 with significant difference